A comprehensive suite of solutions for the screening & infection management of HAIs and MDROs
The efficiency and versatility offered by the BD Max™ System and the Healthcare-Associated Infections (HAIs) portfolio provides a comprehensive suite of solutions on a single, fully automated platform, enabling the laboratory to provide rapid, accurate results which can positively impact patient management.
Each year, hundreds of millions of patients worldwide are affected by HAIs, or infections acquired in healthcare settings, leading to2,3
Significant mortality
Human and economic burden
Prolonged hospital stays
Long-term disability
Increased antimicrobial resistance
Early and accurate detection of HAIs combined with appropriate infection control interventions and patient treatment can:
Support antimicrobial stewardship initiatives
Prevent transmission
Improve patient management
4 million patients in Europe per year acquire an HAI1, at a cost of an estimated €7 billion to healthcare providers.2
Compounding the impact of HAIs are infections due to bacteria resistant to antimicrobials (AMR), many resistant to multiple antimicrobials (MDROs). Therefore, AMR is a major concern in relation to HAIs.
React quickly to outbreaks with up to 120 samples in a 8-hours shift
Increase lab efficiency by decreasing hands-on time for laboratory technicians versus traditional methods
Limit the risk of potential errors and maintain chain of custody including sample transfers and manual manipulations
Flexible testing for HAIs with the capability to run multiple assay types at the same time* * BD assays are run & rack compatible – Only MDR-TB is not run and rack compatible / Vaginal Panel, GBS and open systems’ assays are only run compatible.
Active surveillance of methicillin-resistant Staphylococcus aureus (MRSA) with Extended Detection Technology including mecA and mecC resistance
Surveillance and differentiation of Staphylococcus aureus and MRSA
Detection of toxigenic Clostridioides difficile through the identification of toxin B gene (tcdB)
Active surveillance of vancomycin-resistant enterococci through the detection of vanA and vanB genes
Screening for carbapenemase-producing organism (CPO) through the identification of the five most common carbapenemase genes:
KPC
OXA-48 (OXA-48 and OXA-48 like)
NDM
VIM/IMP
The BD MAX™ System is a single platform
providing you with the versatility of running BD and partner developed assays,
as well as 3rd party and laboratory developed tests.
CPO, Carbapenemase-Producing Organism; CTX, cefotaxime-beta lactamases; ESBL, Extended-Spectrum Beta-Lactamase; HAI, Healthcare-Associated Infections; IMP, imipenemase; KPC, Klebsiella pneumoniae carbapenemase; MDRO, Multidrug-Resistant Organism; MRSA, Methicillin-Resistant Staphylococcus aureus; NDM, New Delhi metallo-β-lactamase; OXA, oxacillinase; SHV, sulphydryl variable; tcdB, toxin B gene; VIM, Verona integron-encoded metallo-β-lactamase
BD, the BD Logo, BD MAX are trademarks of Becton, Dickinson and Company or its affiliates. © 2023 BD. All rights reserved.
The BD MAX System, BD MAX Enteric Bacterial & Extended Enteric Bacterial Panels, BD MAX Enteric Viral Panel & BD MAX Enteric Viral Panel-NR, BD MAX Enteric Parasite Panel, BD MAX Vaginal Panel, BD MAX Check-Points CPO, BD MAX MRSA XT & BD MAX StaphSR, BD MAX Cdiff, BD MAX MDR-TB, BD SARS-CoV-2 Reagents for BD MAX System, BD SARS-CoV-2/Flu for BD MAX System, VIASURE SARS-CoV-2 (N1+N2) Real Time PCR Detection Kit for BD MAX System, VIASURE SARS-CoV-2, Flu (A+B) & RSV Real Time PCR Detection Kit for BD MAX System, VIASURE Flu A, Flu B & RSV Real Time PCR Detection Kit for BD MAX System, VIASURE Vancomycin Resistance Real Time PCR Detection Kit for BD MAX System are in vitro diagnostic medical devices bearing a CE mark.
The BD CTGC2 and BD CTGCTV2 assays for BD MAX System are in vitro diagnostic medical devices bearing a CE mark and are CE certified by BSI Group The Netherlands B.V. (Notified Body Number = 2797).
